Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
An Observational Study on Long-Term Efficacy and Safety of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis (FAct)
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2011-12-01
- Last Posted Date
- 2019-05-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 215
- Registration Number
- NCT01483326
- Locations
- 🇳🇱
Scheper Ziekenhuis, Emmen, Netherlands
🇳🇱Amphia ziekenhuis, locatie langendijk, Breda, Netherlands
🇳🇱Medisch Centrum Twente; Rheumatology, Enschede, Netherlands
A Human Proof of Concept Study for [11C]-RO5011232 as Radiotracer and Study of the Binding of RO4917523 to Human mGlu5 Brain Receptor at Steady-State in Healthy Volunteers
- First Posted Date
- 2011-12-01
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 56
- Registration Number
- NCT01483469
A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2011-11-30
- Last Posted Date
- 2016-08-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 58
- Registration Number
- NCT01482403
A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Participants With Metastatic and/or Locally Advanced Malignant Human Epidermal Growth Factor Receptor (HER3) Expressing Solid Tumors of Epithelial Cell Origin
- Conditions
- Neoplasms
- Interventions
- First Posted Date
- 2011-11-30
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 145
- Registration Number
- NCT01482377
- Locations
- 🇳🇱
Academ Ziekenhuis Groningen; Medical Oncology, Groningen, Netherlands
🇰🇷National Cancer Center, Gyeonggi-do, Korea, Republic of
🇳🇱Antoni van Leeuwenhoek Ziekenhuis, Amsterdam, Netherlands
A Study of Mericitabine in Combination With Telaprevir and Peginterferon Alfa-2a / Ribavirin in Participants With Chronic Hepatitis C
- Conditions
- Hepatitis C
- Interventions
- First Posted Date
- 2011-11-30
- Last Posted Date
- 2017-04-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 80
- Registration Number
- NCT01482390
- Locations
- 🇺🇸
Carolina'S Center For Liver Disease, Statesville, North Carolina, United States
🇺🇸Harborview Medical Center, Seattle, Washington, United States
🇺🇸Birmingham Gastro Associates, P.C., Birmingham, Alabama, United States
An Observational Study of Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer Treated With Herceptin (Trastuzumab) in 1st Line and Without Progression For 3 Years
- First Posted Date
- 2011-11-29
- Last Posted Date
- 2017-08-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 160
- Registration Number
- NCT01480674
- Locations
- 🇫🇷
Ch De Brive La Gaillarde; Radiotherapie Oncologie, Brive La Gaillarde, France
🇫🇷Ch William Morey; Medecine 1, Chalon Sur Saone, France
🇫🇷Centre Jean Perrin; Hopital De Jour, Clermont Ferrand, France
A Study of the Metabolic Profile of Dalcetrapib in Healthy Volunteers
- First Posted Date
- 2011-11-22
- Last Posted Date
- 2019-12-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 6
- Registration Number
- NCT01476267
A Study of RO5028442 in Adult Male High-Functioning Autistic Patients
- First Posted Date
- 2011-11-18
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 19
- Registration Number
- NCT01474278
A Study of Avastin (Bevacizumab) And Fotemustine in Patients With Recurrent Glioblastoma
- Conditions
- Glioblastoma Multiforme
- Interventions
- First Posted Date
- 2011-11-18
- Last Posted Date
- 2016-03-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 91
- Registration Number
- NCT01474239
An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice
- Conditions
- Rheumatoid Arthritis
- Interventions
- Biological: Tocilizumab
- First Posted Date
- 2011-11-18
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 608
- Registration Number
- NCT01474291